Changes to patent laws would speed ac­cess to lower-cost drugs

Modern Healthcare - - Comment -

Re­gard­ing the ar­ti­cle “Branded­drug price hikes dwarf higher uti­liza­tion of lower-cost gener­ics” (ModernHealth­care.com, Nov. 16; also on p. 16 of this is­sue), higher uti­liza­tion of a lower-cost prod­uct? Sounds to me like the generic-drug mar­ket is do­ing ex­actly what we want it to do, and name-brand phar­ma­ceu­ti­cals are be­hav­ing ex­actly as you would ex­pect any in­dus­try would when granted a gov­ern­ment-sanc­tioned mo­nop­oly.

I be­lieve if we con­tinue open­ing the door for gener­ics, the mar­ket will even­tu­ally put down­ward pres­sure on the price of name-brand med­i­ca­tions. But if we want to see that hap­pen faster, we need to do some­thing about the patent laws. Joshua Naat­jes Madi­son, Wis.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.